# SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

> **NCT05461170** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vir Biotechnology, Inc.** · enrollment: 95 (actual)

## Conditions studied

- Hepatitis D, Chronic

## Interventions

- **DRUG:** VIR-2218
- **DRUG:** VIR-3434
- **DRUG:** NRTI

## Key facts

- **NCT ID:** NCT05461170
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-17
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461170, "SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05461170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*